EMBREX INSTALLS INOVOJECT SYSTEM
EMBREX INSTALLS INOVOJECT SYSTEM RESEARCH TRIANGLE PARK, N.C., May 13 /PRNewswire/ -- Embrex Inc.
(NASDAQ: EMBX, EMBXW) today announced that it has signed a leasing agreement with a major U.S. poultry producer for one of Embrex's Inovoject(A) egg injection systems. Before the leasing agreement was signed, the system underwent a series of performance runs at the broiler hatchery where it is now installed.
The lease is for a six-month trial period. The financial terms of the lease and the identity of the leaseholder were not disclosed. Randall L. Marcuson, president and CEO of Embrex, said, "We believe this agreement demonstrates that the in ovo technology embodied in our Inovoject system is being viewed with keen interest by the poultry industry." Marcuson added, "Our strategy is to continue installing Inovoject systems in potential customers' hatcheries and to let them operate the systems to demonstrate the value of our technology." According to Marcuson, Embrex's initial marketing efforts are directed at the major U.S. poultry producers. Embrex estimates the top five U.S. poultry producers account for approximately half of the broiler chickens raised annually. The Inovoject system is an automated egg injection and transfer system which can inoculate 20,000-30,000 fertile eggs per hour. It is intended to replace the labor-intensive, post-hatch manual vaccination of day-old chicks with an automated, in ovo (in-the-egg) vaccination on the 18th day of a broiler egg's 21-day incubation period. Two in ovo vaccines for Marek's disease -- Ovovac-HVT(A) and Ovovac-SB-1(A) -- have been approved by the USDA for use with the Inovoject system and are marketed by Embrex. All of the more than 6.5 billion broiler chickens raised annually in the United States are vaccinated against Marek's disease -- a viral disease of poultry. Embrex Inc. develops and has recently begun marketing bioscience and bioengineering-based products to increase the productivity and profitability of the poultry industry. -0- 5/13/92 /NOTE TO EDITORS: Registered trademark of Embrex Inc./ /CONTACT: Randall Marcuson, president and CEO of Embrex, 919-941-5185; or Douglas Johnson of GreenTree Communications, 800-428-8796, for Embrex/ (EMBX) CO: Embrex Inc. ST: North Carolina IN: MTC SU:
GK -- NY013 -- 9463 05/13/92 08:03 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||May 13, 1992|
|Previous Article:||ARKANSAS BEST COMMENCES INITIAL PUBLIC OFFERING OF 15,700,000 SHARES OF COMMON STOCK; EXTENDS EXPIRATION DATE OF OFFER TO PURCHASE NOTES|
|Next Article:||MARKEL CORPORATION ANNOUNCES FINANCIAL RESULTS|